3 Dokumente gefunden
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit:…
Abstract Purpose Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single-agent cytarabine in consolidation therapy remains elusive. Here, we assessed the impact of different dosages of…
Berlin: Springer, 2022-09-28
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
Background: The role of allogeneic hematopoietic cell transplantation (alloHCT) in acute myeloid leukemia (AML) with mutated IDH1/2 has not been defined. Therefore, we analyzed a large cohort of 3234 AML patients in first complete remission (CR1) undergoing alloHCT or conventional chemo-consolidation…
London: BioMed Central, 2022-09-05
